Company / Operating Cash Flow
BioMarin Pharmaceutical Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$828.0M
FY2025
5-year range
$159.3M / $828.0M
FY2021-FY2025
Trend
+44.5%
vs FY2024
Sector context
#23 of 216
Health Care
What the data says
BioMarin Pharmaceutical's operating cash flow of $828M is higher than 89% of companies in the Health Care sector (FY2025). Improved from $159M to $828M over the past 2 years.
Based on SEC 10-K filings.
$828M in FY2025 with a 5-year CAGR of +57.5%. Top quartile in the Health Care sector.
Improved from $159M to $828M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +67.6%
- 5-Year CAGR
- +57.5%
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 216This company $828.0M Sector average $658.7M
▼
+25.7% above sector average
Key checks
Key Insights
- 5-year CAGR of +57.5%, indicating consistent growth.
- In FY2025, operating cash flow increased 44.5% year-over-year.
- Ranks #23 out of 216 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $828.0M | +44.5% |
| FY2024 | $572.8M | +259.7% |
| FY2023 | $159.3M | -9.5% |
| FY2022 | $175.9M | -42.2% |
| FY2021 | $304.5M | +256.7% |
| FY2020 | $85.4M | +76.9% |
| FY2019 | $48.3M | +138.8% |
| FY2018 | $20.2M | +330.8% |
| FY2017 | -$8.8M | +96.2% |
| FY2016 | -$227.8M | -3.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026